An interventional study of Targeted CRC Screening Toolkit in Colorectal Cancer Screening and Diabetes Mellitus, Type 2, sponsored by Rutgers, The State University of New Jersey. Completed at 1 site in United States. Open to participants aged 50 Years to 74 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-06.
Sponsored by Rutgers, The State University of New Jersey · Not applicable, Interventional, and Health services research
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies in Diabetes Mellitus, Type 2 by Rutgers, The State University of New Jersey — 5 open to participants now, 5 under way, 1 of them phase 3. Diabetes Mellitus, Type 2 · Rutgers, The State University of New Jersey.
Among the 12 studies in Diabetes Mellitus, Type 2 by Rutgers, The State University of New Jersey, this one is the 11th largest by enrollment, is the only one that started in 2022, is one of 11 with no phase, and was the 5th registered.
10,403 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →5 of the 12 studies in Diabetes Mellitus, Type 2 by Rutgers, The State University of New Jersey are open now, in 1 country. Recruiting first, the newest first:
Rutgers, The State University of New Jersey · Sites in United States
Ages 55–80
Rutgers, The State University of New Jersey · Sites in United States
Ages 18–90
Rutgers, The State University of New Jersey · Sites in United States
Ages 30–80 · Healthy volunteers
Rutgers, The State University of New Jersey · Sites in United States
Ages 18+
Rutgers, The State University of New Jersey
Ages 40–70 · Healthy volunteers
By country, each count listing its studies:
Of the 882 Diabetes Mellitus, Type 2 studies recruiting now, 372 (42%) set no upper age limit and 384 (44%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.
This study: 50 Years to 74 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
First in 2015; this study’s year is marked. 1 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 13 is below the median of 80 across 8,372 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 54 across the 12 interventional studies. Of the 6 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Rutgers, The State University of New Jersey is the lead sponsor of 507 studies on the registry; 132 are open to participants now.
Of its 39 completed or terminated interventional studies of FDA-regulated products, 31 (79%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 12 studies in Diabetes Mellitus, Type 2 by Rutgers, The State University of New Jersey, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This mixed methods study evaluates the effectiveness and feasibility of a multi-level (patient, team, organizations) intervention to optimize CRC screening for patients with diabetes in primary care safety-net settings.
Aim 3 is a hybrid type 2 effectiveness-implementation pilot study in six primary care safety net clinics. This single-arm study uses a pre-post design to evaluate the targeted implementation strategies impact on: (1) preliminary effectiveness and (2) implementation (i.e., feasibility and acceptability) and a mixed-method comparative case study learning evaluation for safety-net primary care adoption and implementation. Implementation strategies that will be tested were developed through a stakeholder engaged, community-based participatory implementation planning approach. This study uses a tailored combination of implementation strategies that include but are not limited to: identification of patient and practice-level barriers, patient education matierals, patient reminders provider/clinical team education, clinical champions, and audit and feedback. The impact of this evaluation will be measure using mixed methods to assess Exploration, Preparation, Implementation factors related to how organizational and contextual variables affect adoption and implementation for targeting CRC screening among patients with diabetes in safety net clinics at 12 months post intervention. Aim 3 surveys 20 clinicians and staff from 6 clinics (n=120) and conducts key-informant interviews with 8 clinic and staff members at pre- and post-implementation (who have participated in the survey; n=96) and evaluates aggregate data for 30 patients across six clinics (n=180).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Based on national survey data and a community engagement participatory implemention planning group, a tailored combination of widely accepted implementation strategies will be adapted for targeting CRC screening for patients with diabetes. These strategies include but are not limited to: identification of patient and practice-level barriers, patient education, provider reminders, and audit and feedback.
Behavioral: Targeted CRC Screening Toolkit
Strategies in the toolkit include but are not limited to: identification of patient and practice-level barriers, routine tailored patient reminders, provider reminders, \& clinic staff feedback.
Colonoscopy uptake
Preliminary effectiveness: Clinic-level proportion of participants who complete a colonoscopy
Time frame: 12 months
Up-to-date CRC screening
Preliminary Effectiveness: Clinic-level proportion of participants who receive any CRC screening
Time frame: 12 months
Rate of CRC Screening Uptake by Glucose Control (Controlled vs. Uncontrolled) Among Participants with Type 2 Diabetes
Preliminary Effectiveness: Clinic-level CRC screening by glucose control (controlled vs. uncontrolled)
Time frame: 12 months
Participant Acceptability
Implementation: participants opt-out and non-adherence rates based on proportion of overall eligible participants
Time frame: 12 months
Implementation Fidelity
Clinic-level proportion of eligible participants who were contacted for screening based on implementation plan targets
Time frame: 12 months
Plan to share: No
Ran from Nov 2022 to primary completion in Jul 2026, 44 months.
Of 2,078 non-industry interventional studies with no phase under Diabetes Mellitus, Type 2, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 40. This study's 44 months is above that.
Counting every sponsor, half of 2,255 studies reached it within 21 months; a quarter within 10 and three quarters within 39.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 6, 2026: primary completion Sep 2026 → Jul 2026 and completion Sep 2026 → Jul 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Rutgers, The State University of New Jersey →